CL2023000926A1 - Inhibidores alostéricos de akt para su uso en el tratamiento de telangiectasia hemorrágica hereditaria - Google Patents
Inhibidores alostéricos de akt para su uso en el tratamiento de telangiectasia hemorrágica hereditariaInfo
- Publication number
- CL2023000926A1 CL2023000926A1 CL2023000926A CL2023000926A CL2023000926A1 CL 2023000926 A1 CL2023000926 A1 CL 2023000926A1 CL 2023000926 A CL2023000926 A CL 2023000926A CL 2023000926 A CL2023000926 A CL 2023000926A CL 2023000926 A1 CL2023000926 A1 CL 2023000926A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- hereditary hemorrhagic
- hemorrhagic telangiectasia
- akt inhibitors
- allosteric akt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2015536.2A GB2600384A (en) | 2020-09-30 | 2020-09-30 | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023000926A1 true CL2023000926A1 (es) | 2023-11-03 |
Family
ID=73197201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023000926A CL2023000926A1 (es) | 2020-09-30 | 2023-03-29 | Inhibidores alostéricos de akt para su uso en el tratamiento de telangiectasia hemorrágica hereditaria |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12466839B2 (https=) |
| EP (1) | EP4221713A1 (https=) |
| JP (1) | JP2023543993A (https=) |
| KR (1) | KR20230080448A (https=) |
| CN (1) | CN116419924A (https=) |
| AU (1) | AU2021352108B2 (https=) |
| BR (1) | BR112023004885A2 (https=) |
| CA (1) | CA3192433A1 (https=) |
| CL (1) | CL2023000926A1 (https=) |
| GB (1) | GB2600384A (https=) |
| IL (1) | IL301466A (https=) |
| MX (1) | MX2023002996A (https=) |
| WO (1) | WO2022069552A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2600384A (en) | 2020-09-30 | 2022-05-04 | Vaderis Therapeutics Ag | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
| WO2026038045A1 (en) | 2024-08-15 | 2026-02-19 | Almac Discovery Limited | Crystalline forms of 6-(4-((1s,3s)-1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1h-pyrido[2,3-b][1,4]oxazin-2(3h)-one salts and free base |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI301760B (en) | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
| US7910561B2 (en) | 2004-12-15 | 2011-03-22 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| EP1898903B8 (en) | 2005-06-10 | 2013-05-15 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| WO2008011032A1 (en) | 2006-07-17 | 2008-01-24 | Amgen Inc. | Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors |
| AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| JP2010512312A (ja) | 2006-12-06 | 2010-04-22 | メルク エンド カムパニー インコーポレーテッド | Ａｋｔ活性の阻害剤 |
| US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
| JP2011522048A (ja) | 2008-06-03 | 2011-07-28 | メルク・シャープ・エンド・ドーム・コーポレイション | Ａｋｔ活性の阻害剤 |
| US8536193B2 (en) | 2008-06-03 | 2013-09-17 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| EP2116237A1 (en) | 2008-08-05 | 2009-11-11 | Polichem SA | Compositions for treating rosacea comprising chitosan and a dicarboxylic acid |
| EA201101186A1 (ru) | 2009-02-13 | 2012-04-30 | Байер Фарма Акциенгезельшафт | Конденсированные пиримидины |
| GB0922589D0 (en) | 2009-12-23 | 2010-02-10 | Almac Discovery Ltd | Pharmaceutical compounds |
| HUE026323T2 (en) | 2011-04-07 | 2016-05-30 | Bayer Ip Gmbh | Imidazopyridazines as akt kinase inhibitors |
| EP3294314A4 (en) | 2015-05-15 | 2019-01-16 | Memorial Sloan Kettering Cancer Center | USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES |
| MX2020002611A (es) | 2017-09-07 | 2020-07-13 | Univ Res Inst Inc Augusta | Activador especifico de akt3 y usos del mismo. |
| GB2600384A (en) | 2020-09-30 | 2022-05-04 | Vaderis Therapeutics Ag | Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia |
-
2020
- 2020-09-30 GB GB2015536.2A patent/GB2600384A/en not_active Withdrawn
-
2021
- 2021-09-29 KR KR1020237014688A patent/KR20230080448A/ko active Pending
- 2021-09-29 WO PCT/EP2021/076811 patent/WO2022069552A1/en not_active Ceased
- 2021-09-29 AU AU2021352108A patent/AU2021352108B2/en active Active
- 2021-09-29 BR BR112023004885A patent/BR112023004885A2/pt unknown
- 2021-09-29 CN CN202180066598.2A patent/CN116419924A/zh active Pending
- 2021-09-29 CA CA3192433A patent/CA3192433A1/en active Pending
- 2021-09-29 JP JP2023519016A patent/JP2023543993A/ja active Pending
- 2021-09-29 EP EP21789616.6A patent/EP4221713A1/en active Pending
- 2021-09-29 US US18/247,261 patent/US12466839B2/en active Active
- 2021-09-29 IL IL301466A patent/IL301466A/en unknown
- 2021-09-29 MX MX2023002996A patent/MX2023002996A/es unknown
-
2023
- 2023-03-29 CL CL2023000926A patent/CL2023000926A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240092801A1 (en) | 2024-03-21 |
| AU2021352108A1 (en) | 2023-05-11 |
| CN116419924A (zh) | 2023-07-11 |
| GB2600384A (en) | 2022-05-04 |
| WO2022069552A1 (en) | 2022-04-07 |
| EP4221713A1 (en) | 2023-08-09 |
| JP2023543993A (ja) | 2023-10-19 |
| MX2023002996A (es) | 2023-05-03 |
| KR20230080448A (ko) | 2023-06-07 |
| CA3192433A1 (en) | 2022-04-07 |
| GB202015536D0 (en) | 2020-11-11 |
| AU2021352108B2 (en) | 2026-04-02 |
| US12466839B2 (en) | 2025-11-11 |
| BR112023004885A2 (pt) | 2023-04-18 |
| IL301466A (en) | 2023-05-01 |
| AU2021352108A9 (en) | 2024-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001158A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| CO2022015638A2 (es) | Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso | |
| UY38696A (es) | Moduladores de alfa-1 antitripsina | |
| MX2021002804A (es) | Terapias de combinacion. | |
| CO2026004964A2 (es) | Moduladores de kras | |
| MX2024001894A (es) | Compuestos heterociclicos y metodos de uso. | |
| MX2023004593A (es) | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. | |
| MX2024010399A (es) | Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias | |
| ECSP23057264A (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
| CL2019000368A1 (es) | Inhibidores de cdk2/4/6. | |
| AR119206A1 (es) | DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR | |
| PE20200335A1 (es) | Compuestos que inhiben la proteina mcl-1 | |
| SV2010003567A (es) | Derivados bis-(sulfonilamino) en terapia 066 | |
| MX2024008551A (es) | Terapias de combinacion. | |
| MX2022002976A (es) | Inhibidores selectivos de jak1. | |
| DOP2010000191A (es) | Derivados bis-(sulfonilamino) | |
| DOP2009000159A (es) | Inhibidores de la poli(adp-ribosa) polimerasa | |
| CL2023000926A1 (es) | Inhibidores alostéricos de akt para su uso en el tratamiento de telangiectasia hemorrágica hereditaria | |
| UY30298A1 (es) | Inhibidores de la quinasa c-fms ii | |
| MX2022000550A (es) | Imidazopirimidinas como inhibidores de eed y uso de estas. | |
| MX2023014466A (es) | Derivados de piridopirimidina útiles como inhibidores de cinasa wee1. | |
| CL2024002623A1 (es) | Formas solidas, sales y procesos de preparacion de un inhibidor de cdk2. | |
| MX2025014135A (es) | Compuestos inhibidores de cinasa dependiente de ciclina para el tratamiento de trastornos medicos | |
| CL2007002381A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno susu sales, solvatos o isomeros y uso de la combinacion con al menos un compuesto seleccionado entre diclofenaco, un corticosteroide, un antibiotico, un analgesico, un inmunomodulador, entre otros, para el tratamiento o profilaxis de la dermatitis | |
| MX2019006843A (es) | Inhibidor de cdk4/6. |